Information  X 
Enter a valid email address

Feedback PLC (FDBK)

  Print          Annual reports

Wednesday 28 October, 2020

Feedback PLC

Director/PDMR Shareholding

RNS Number : 5199D
Feedback PLC
28 October 2020
 

Feedback plc

 

Director/PDMR Shareholding

 

London , UK, 28  October  2020   Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, has been informed that Rory Shaw, Non-Executive Chairman of the Company, has today purchased 5,235,446 ordinary shares in the Company ("Ordinary Shares") at an average price of 0.992 pence per Ordinary Share.

 

Following this purchase, Rory Shaw has a total beneficial interest in 9,818,780 Ordinary Shares, equivalent to approximately 0.92 per cent. of the Company's issued share capital.

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

[email protected]



Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656



Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey

+44 (0)20 7469 0936



Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 20 3815 8880



Walbrook PR Ltd

Tel: 020 7933 8780 or  [email protected]

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

Notes to Editors  

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go. 

Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

N otification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Rory Shaw 

2

Reason for the notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  

a) 

Name

Feedback plc

b) 

LEI

213800UGOF2GT2U2RV90

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 0.25p each in Feedback   plc

 

 

Identification code (ISIN) for Feedback plc ordinary shares: GB0003340550

b)

Nature of the transaction

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

1.0334p

1,156,570

0.9948p

1,005,227

0.9896p

1,010,509

0.95p

1,052,631

0.9896p

1,010,509

d)

 

Aggregated information

- Aggregated volume

- Price

- Principal amount 

 

Aggregated volume: 5,235,446

Volume weighted average price: 0.992p

Principal amount: £51,951.98

 

e)

Dates of the transaction

28 October 2020

f)

Place of transaction

London Stock Exchange

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPGQUUUPUGAR

a d v e r t i s e m e n t